RenovoRx Appoints Biotech Veteran Rothberg to Board

Ticker: RNXT · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1574094

Renovorx, INC. 8-K Filing Summary
FieldDetail
CompanyRenovorx, INC. (RNXT)
Form Type8-K
Filed DateMar 14, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$325,000, $1.69
Sentimentneutral

Sentiment: neutral

Topics: board-change, appointment

TL;DR

RenovoRx adds biotech founder Rothberg to its board.

AI Summary

RenovoRx, Inc. announced on March 14, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has been appointed to the Board of Directors, effective March 8, 2024. Dr. Rothberg is a notable figure in the biotech industry, known for founding several companies.

Why It Matters

The addition of a prominent figure like Dr. Rothberg, with a track record of founding successful biotech ventures, could signal strategic growth or new directions for RenovoRx.

Risk Assessment

Risk Level: medium — Board changes can introduce new strategic directions or potential conflicts, impacting the company's future performance.

Key Players & Entities

FAQ

Who is Dr. Jonathan M. Rothberg and what is his background?

Dr. Jonathan M. Rothberg is a notable figure in the biotech industry, known for founding several companies, though specific details of his past ventures are not elaborated upon in this filing.

When was Dr. Rothberg's appointment effective?

Dr. Rothberg's appointment to the Board of Directors was effective March 8, 2024.

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily to report the election of a director to the company's board.

What is RenovoRx, Inc.'s principal executive office address?

RenovoRx, Inc.'s principal executive offices are located at 4546 El Camino Real, Suite B1, Los Altos, CA 94022.

What is the Commission File Number for RenovoRx, Inc.?

The Commission File Number for RenovoRx, Inc. is 001-40738.

Filing Stats: 723 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-14 16:53:16

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: March 14, 2024 By: /s/ Shaun Bagai Name: Shaun R. Bagai Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing